A retrospective analysis of the clinical benefits of continuing crizotinb beyond initial PD (CBPD) concluded that a longer overall survival was achieved in patients with advanced ALK-positive NSCLC [9]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.